Healthcare webinar

How Huma and iPLATO (myGP) advance digital-first delivery of care

Watch Huma and iPLATO's webinar on demand to see how remote patient monitoring can help clinicians provide better care to patients 

Huma’s CEO Dan Vahdat, iPLATO’s CEO Tobias Alpsten and North West London ICS Primary Care Clinical Lead Dr Kuldhir Johal discuss:

  • How the NHS uses digital tech to meet challenges in primary and secondary care
  • Case study: How digital innovation has supported patients during the pandemic and how it can transform other disease pathways
  • The power of digital to engage people in their health and make personalised medicine a reality

Register here to watch on demand 



More about the speakers

5. Dan V
Dan Vahdat, CEO and Founder of Huma



Welcoming iPLATO to the Huma family

In January 2022, Huma acquired iPLATO to enable more proactive, predictive and personalised primary and secondary care for patients.

iPLATO has over 10 years of experience in primary care engagement and its patient engagement technology covers a network of 26.6m patients across nearly 3,000 NHS organisations. The company’s myGP app is one of the most downloaded medical apps in the UK.

Almost 2.4m people in England use myGP to manage their health – reducing unnecessary appointments, administrative tasks, and pressure on primary care; including medication reminders, tracking of vital signs and ordering of prescriptions. iPLATO has also been instrumental in increasing uptake of NHS services, including IAPT services, cancer screenings and health checks, resulting in up to 65% higher uptake of services communicated through the myGP platform.


Why we acquired iPLATO

We are part of the movement using remote patient monitoring and digital biomarkers to transform healthcare. iPLATO recently launched patient questionnaires on the myGP platform to enable patient data to be coded directly into the patients’ medical records. Working together, Huma and iPLATO can combine tools like this with digital biomarkers to help create a world where we can tackle the biggest killers of our time - cancer, heart disease and now, Covid-19.

We also want to introduce digital screening and our peer-reviewed cardiovascular and depression risk scores to give patients even more insight into their own health. Adding these capabilities to iPLATO’s patient engagement expertise gives us the opportunity to make a significant difference in primary care and help more patients to live longer, fuller lives.